The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically
well established as attractive therapeutic targets. During investigation of trends within …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Chemotherapy is one of the most established and effective treatments for almost all types of
cancer. However, the elevated toxicity due to the non-tumor-associated effects, development …

Genomic alterations may make cancer cells more dependent than normal cells on
mechanisms of proteostasis, including protein folding and degradation. This proposition is …

Defects in chromatin modifiers and remodelers have been described both for hematological
and solid malignancies, corroborating and strengthening the role of epigenetic aberrations …

A multitude of new agents for the treatment of hematologic malignancies has been
introduced over the past decade. Hematologists, infectious disease specialists, stem cell …

Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating
clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease. An …

In the USA at the beginning of this century, the average overall survival in patients with
multiple myeloma was about 3 years. Around that time, three drugs (bortezomib …